on both the top and bottom lines. The pharmaceutical giant raised its revenue outlook based on surging demand for its weight-loss drugs, Mounjaro and Zepbound.
S the company blue past analysts expectations in its second quarter, also raised its full year revenue outlook here for a deeper dive into these results.He is mzs Health Care Equity strategist, Jared lots to talk about here within this report, but at least on the surface or really what's driving the action is a lot of the excitement surrounding the weight loss drugs.Of course, one of the questions going into this print was the ability to meet demand.
So as soon as capacity kind of starts rolling here, I think you're gonna see a lot of upside to numbers for the next few years. You know, some of the compounders have been able to find success here early on because of the supply issues at Novo and Lily. So I think for most patients, they want the branded product, the inability to get it has been the gating factor.
“Saturday Night” Trailer Rewinds to 1975 for Uncanny Look at “SNL”'s Chevy Chase, John Belushi and More
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: YahooFinanceCA - 🏆 47. / 63 อ่านเพิ่มเติม »